Fundamental Analysis of Kiora Pharmaceuticals Inc - Growth / Value Index


KPRX - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Good Score of 65.62
   Price to Earning Ratio is 3.33 and EV to EBITDA is 4.78 suggesting company is undervalued.
   Price to Book Ratio is 0.519 indicating that it is undervalued.
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 2.88 -0.187 -604.79 %
Price to Book 0.449 0.391 1134.58 % 0.495
Price to Sales 0.402 0 0 %
Enterprise Value to EBITDA Multiple 4.01 0.0016 -99.61 %


KPRX - Profitability Highlights

Profitability Analysis

   Earning Yield of 30.07 %
   Steady Growth in EPS for last four quarters
   Good Return on Equity of 15.61% is achieved by the company
   Good Net Margin of 13.98% is achieved by the company
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 15.61 -208.58 -75.17 % 38.54
Return On Asset 10.50 -92.94 -27.80 % 31.70
Net Profit Margin 13.98 0 0 % 84.08
Operating Profit Margin 14.07 0 0 % 82.56
EBITDA Margin 16.12 0 0 % 82.66


Highlights
Market Cap12944.31 K
Enterprise Value10536.69 K
Price/Book TTM0.449
Outstanding Share26256.20 K
Float/ Outstanding Share50.19%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0.223
Peter Lynch Ratio0
Piotroski F Score3.00
Altman Z Score-16.78
Sloan Ratio-0.265
Peter Lynch Fair Value0


KPRX - Growth Highlights

Growth Analysis

   Quarterly sales in last 5 years is trending up
   Annual sales in last 3 years is trending down
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 16283.87 K % 5536.34 %
Gross Profit 15876.77 K 53.42 % 201534 %
EBITDA 2624.63 K 5.45 % 766.55 %
Net Profit 2276.86 K 6.18 % 693.02 %
EPS 0.171 85.81 % NA


KPRX - Stability Highlights

Stability Analysis

   Paid More Than 50% of Debt, Heading towards debt free
   Debt to equity ratio has decreased and is lowest in last three years
   Tsr Stability Index - Poor Score of 29.69
   Altman Z Score of -16.62 suggest high risk
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -1144.78
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0077 -16.92 % 0.0014
Cash Ratio 1.50 -17.58 %
Quick Ratio 2.90 0 % 21.02
Shareholders Equity 44.56 -27.04 %
Debt to EBITDA -0.0037 52.94 %


Historical Valuation Ratios of Kiora Pharmaceuticals Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Kiora Pharmaceuticals Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Kiora Pharmaceuticals Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Kiora Pharmaceuticals Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)